Introduction to Liver Sinusoid Engineering

Fontan-associated liver disease (FALD) remains a significant and progressive complication for patients living with single-ventricle physiology. Recently, breakthroughs in bioengineering have introduced a sophisticated Fontan-associated liver disease model to better understand the underlying mechanics of this condition. This 3D bioengineered human liver sinusoid incorporates both hepatocytes and endothelial cells within a multilayered construct. Consequently, it allows researchers to study the complex interaction between chronically elevated central venous pressure (CVP) and hypoxia that defines Fontan physiology.

Pathophysiology in the Fontan-Associated Liver Disease Model

The new platform utilizes a perfusable architecture that mimics the liver's natural microenvironment. Furthermore, the model operates under tunable flow and oxygen levels to replicate the pathological CVP levels seen in clinical cases. Because the researchers employed electron microscopy and microindentation, they confirmed the structural and mechanical fidelity of the sinusoid analogues. Therefore, this model provides a highly accurate representation of human liver tissue responses to hemodynamic stress. Specifically, the sinusoid analogues maintained their endothelial coverage and hepatic viability over 21 days of culture.

Molecular Responses to Pressure and Hypoxia

During the study, researchers observed that elevated pressure and hypoxia triggered specific cellular pathways associated with FALD. Specifically, endothelial activation occurred through the expression of VCAM-1 and ET-1. Additionally, hepatocellular stress was evident by the presence of HIF1α. These molecular changes led to fibronectin-rich tissue remodeling and altered hepatic functions, including changes in albumin and bile acid production. Consequently, these findings align closely with the early-stage FALD pathology observed in pediatric and adult patients. This bioengineered model successfully reproduced key features of liver injury, enabling a controlled environment for mechanistic interrogation.

Implications for Therapeutic Discovery

The platform's high sensitivity to metabolic and mechanical cues makes it an ideal tool for testing novel therapeutic interventions. Moreover, the ability to maintain hepatic function in a perfusable system for three weeks allows for long-term study of disease progression. This innovation enables controlled interrogation of liver injury without relying solely on limited animal models. Ultimately, this progress in modeling may lead to improved diagnostic markers and personalized treatment strategies for patients surviving the Fontan procedure.

Frequently Asked Questions

What is the primary cause of Fontan-associated liver disease?

FALD is primarily driven by the chronically elevated central venous pressure and reduced pulsatile blood flow inherent in Fontan circulation, which leads to hepatic congestion and hypoxia.

How does the 3D liver model improve FALD research?

Unlike traditional cell cultures, this 3D model incorporates multiple cell types and tunable hemodynamic flow, accurately mimicking the mechanical and metabolic stresses that cause liver injury in Fontan patients.

What biomarkers were identified in this study?

The study highlighted several biomarkers of injury, including endothelial activation markers like VCAM-1 and ET-1, as well as the hypoxia-inducible factor HIF1α and changes in albumin and LDH levels.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or to replace the professional judgment of a healthcare provider. Refer to the latest local and national guidelines for clinical practice.

References

1. Rezapourdamanab S et al. A Dynamic 3D Human Liver Sinusoid Model for Mechanistic Interrogation of Fontan-Associated Liver Disease. Adv Sci (Weinh). 2026 Apr 08. doi: 10.1002/advs.202524337. PMID: 41949899.

2. Munsterman ID et al. Liver fibrosis in the Fontan circulation: A review. World J Hepatol. 2019.

3. Rychik J et al. The Fontan survivor: A review of liver issues. Cardiology in the Young. 2013.